Immunotherapy for osteosarcoma
Osteosarcoma (OS) is the most common malignant bone tumor and often occurs in children. Chemotherapy with methotrexate, cisplatin, doxorubicin, and ifosfamide has greatly improved the prognosis of patients with OS, and most patients have been able to preserve their limbs. However, no progress has be...
Main Authors: | Kenichiro Yahiro, Yoshihiro Matsumoto |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-05-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2020.1824499 |
Similar Items
-
Advances on immunotherapy for osteosarcoma
by: Shengnan Yu, et al.
Published: (2024-09-01) -
Current Status and Prospects of Immunotherapy for Osteosarcoma
by: WU Wei, et al.
Published: (2022-07-01) -
Novel Immunotherapies for Osteosarcoma
by: Yubao Lu, et al.
Published: (2022-04-01) -
Make it STING: nanotechnological approaches for activating cGAS/STING as an immunomodulatory node in osteosarcoma
by: Jordan C. O’Donoghue, et al.
Published: (2024-09-01) -
Immunotherapy of osteosarcoma based on immune microenvironment modulation
by: Heping Lian, et al.
Published: (2025-01-01)